Navigation Links
Carl A. Miller, PhD, Joins iDiverse's Business and Scientific Advisory Board
Date:1/11/2011

DEL MAR, Calif., Jan. 12, 2011 /PRNewswire/ -- iDiverse today announced that Dr. Carl A. Miller has joined the company's Business and Scientific Advisory Board.

"We are extremely pleased to have Dr. Miller join our team at this time," said John Burr, president and CEO of iDiverse. "Dr. Miller has over forty years of extensive, hands on experience in the commercialization of novel bio-based technologies that have greatly improved the economics of production of biofuels and biomaterials. He has been directly involved in solving some of the very difficult problems associated with the pretreatment and fermentation of biomass materials to biofuels and chemicals. We believe our technology can play a significant role here and I am looking forward to Dr. Miller's help and support."

"I believe that iDiverse's technology will play an immediate role in overcoming many of the generally accepted limitations in the production of biofuels from a wide variety of fermentation substrates. The iDiverse technologies represent breakthroughs in the conventional paradigm of biofuel production from any feedstock but its greatest impact will be realized in the biomass-to-biofuels sector," said Dr. Miller.

Dr. Miller has an expansive background ranging from the development of cost-effective biofuel production process designs to the commercialization of novel industrial enzymes. He has held positions at Novozymes, Gist-brocades (now DSM), Diversa (now Verenium), Innovase and Syngenta, and is currently the president of Enventek, a biotechnology consulting company. Dr. Miller earned his PhD in bio-organic chemistry from Clemson University and did post-doctoral work on enzyme mechanism at Syracuse University.

About iDiverse

iDiverse, Inc. is a privately-held biotechnology company dedicated to developing and commercializing genetically enhanced cell lines for use in the bioproduction of fuel ethanol, industrial enzymes, and pharmaceuticals. It also provides genetic technology for creating plants that are resistant to a wide range of biological and environmental stresses.


'/>"/>
SOURCE iDiverse, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Paul Pospisil Joins Korn/Ferry as Senior Client Partner in Biotechnology and Life Sciences Practice
2. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
3. Dr. Russell L. Chapman Joins Aquatic Energy as the Chairman of its Science Advisory Board
4. Dr. Michael Hanley Joins Celtaxsys as CEO
5. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
6. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
7. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
8. Todd Park, Chief Technology Officer of U.S. Department of Health and Human Services, Joins Opening Keynote Line-Up at 2010 mHealth Summit
9. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
10. Excerpta Medica Joins Adelphi Worldwide
11. Philadelphia Eagles Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):